Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma

Cancer Cell. 2011 Aug 16;20(2):143-57. doi: 10.1016/j.ccr.2011.07.007.

Abstract

Despite the histological similarity of ependymomas from throughout the neuroaxis, the disease likely comprises multiple independent entities, each with a distinct molecular pathogenesis. Transcriptional profiling of two large independent cohorts of ependymoma reveals the existence of two demographically, transcriptionally, genetically, and clinically distinct groups of posterior fossa (PF) ependymomas. Group A patients are younger, have laterally located tumors with a balanced genome, and are much more likely to exhibit recurrence, metastasis at recurrence, and death compared with Group B patients. Identification and optimization of immunohistochemical (IHC) markers for PF ependymoma subgroups allowed validation of our findings on a third independent cohort, using a human ependymoma tissue microarray, and provides a tool for prospective prognostication and stratification of PF ependymoma patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adult
  • Brain Neoplasms / classification*
  • Brain Neoplasms / genetics
  • Chromosome Aberrations
  • Cranial Fossa, Posterior / pathology*
  • Ependymoma / classification*
  • Ependymoma / genetics
  • Female
  • Gene Expression Profiling
  • Humans
  • Male
  • Middle Aged